Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical considerations for the design of PROTACs in cancer

7 Mar 2022

Abstract excerpt

Degradation of targeted proteins using proteolysis targeting chimeras (PROTACs) has gained momentum. A PROTAC is a bifunctional molecule that consists of three parts: a ligand that interacts with the protein to be degraded, another ligand that binds to an E3 ubiquitin ligase and a linker that connects both. Identification of the right proteins as targets to be degraded and a ligase that is highly expressed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35249548
DOI: 10.1186/s12943-022-01535-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical considerations for the design of PROTACs in cancerPMID 35249548Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read ↗

Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat CancerSemantic proximity Read ↗

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read ↗

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent KinaseSemantic proximity Read ↗

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung CancerSemantic proximity Read ↗

Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor DegradationSemantic proximity Read ↗

Clinical Translation of Targeted Protein DegradersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.